Adaptive biotechnologies stock.

About Adaptive Biotechnologies Stock. Adaptive Biotechnologies aims to help scientists look at the immune system in a new way, with a combination of DNA sequencing and high-powered computation, to analyze the DNA sequences that make up the immune system. Unlike other cell types, which operate on a fixed set of code from the human genome, immune ...

Adaptive biotechnologies stock. Things To Know About Adaptive biotechnologies stock.

Mr. Goel ADPT stock SEC Form 4 insiders trading. David has made over 6 trades of the Adaptive Biotechnologies stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 466,176 units of ADPT stock worth $13,463,163 on 14 May 2014.. The largest trade he's ever made was selling 1,000,000 units of Adaptive …Before we jump into Adaptive Biotechnologies Corp’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background. Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to …The stock is down 50% post the news. ... Some other top-ranked stocks in the overall healthcare sector include Adaptive Biotechnologies Corporation ADPT, ...SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended ...Watch Adaptive Biotechnologies stock price move in real-time ahead here. On February 14, Adaptive Biotechnologies will release earnings for the most recent quarter.

Adaptive Biotechnologies shares are trading down 2.6% at $37.12 at the time of this writing on Monday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete ...The latest closing stock price for Adaptive Biotechnologies as of November 24, 2023 is 4.37. The all-time high Adaptive Biotechnologies stock closing price was 67.74 on …SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...

Looking for the best gutter downspout adapters and components? We put together the top 8 models for your next gutter project. Expert Advice On Improving Your Home Videos Latest View All Guides Latest View All Radio Show Latest View All Podc...May 26, 2023 · The growth-stock investor added to her stakes in UiPath (PATH 26.72%), Prime Medicine (PRME 11.02%), and Adaptive Biotechnologies (ADPT 7.31%) on Thursday. What does Wood see in these three ...

Nov 30, 2023Adaptive Biotechnologies Corp is down 12.44% from its previous closing price of $7.96. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $7.87 and $8.10. Currently, there are 143.51 million shares of Adaptive Biotechnologies Corp stock available for purchase. Unfortunately, Adaptive Biotechnologies Corp’s ...Jul 10, 2023 · Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023. 11-02-2023 at 4:07 PM EDT. Adaptive Announces Launch of Epic Integration for clonoSEQ®. 09-13-2023 at 7:31 AM EDT. Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference. 08-30-2023 at 4:30 PM EDT. Discover historical prices for ADPT stock on Yahoo Finance. View daily, weekly or monthly format back to when Adaptive Biotechnologies Corporation stock was issued.The consensus among analysts is that Adaptive Biotechnologies Corp (ADPT) is an Overweight stock at the moment, with a recommendation rating of 1.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 8 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight.

Before we jump into Adaptive Biotechnologies Corp’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background. Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to …

The Investor Relations website contains information about Adaptive Biotechnologies's business for stockholders, potential investors, and financial analysts.

4.3500. -0.1600. -3.55%. SEATTLE, April 06, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company ...May 3, 2023 · Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.44 per share a year ago. These ... View today's Adaptive Biotechnologies Corp stock price and latest ADPT news and analysis. Create real-time notifications to follow any changes in the live stock price.Adaptive Biotechnologies (ADPT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look ...Mr. Goel ADPT stock SEC Form 4 insiders trading. David has made over 6 trades of the Adaptive Biotechnologies stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 466,176 units of ADPT stock worth $13,463,163 on 14 May 2014.. The largest trade he's ever made was selling 1,000,000 units of Adaptive …On average, Wall Street analysts predict. that Adaptive Biotechnologies's share price could reach $8.00 by Nov 13, 2024. The average Adaptive Biotechnologies stock price prediction forecasts a potential upside of 83.07% from …

Adaptive Biotechnologies: Stock Isn't Cheap. Jun. 04, 2021 4:10 PM ET Adaptive Biotechnologies Corporation (ADPT) 7 Comments 3 Likes. Avisol Capital Partners. Investing Group Leader. Follow.Nov 29, 2023 · Stock analysis for Adaptive Biotechnologies Corp (ADPT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...With Adaptive Biotechnologies stock trading at $4.15 per share, the total value of Adaptive Biotechnologies stock (market capitalization) is $600.28M. Adaptive Biotechnologies stock was originally listed at a price of $40.30 in Jun 27, 2019. If you had invested in Adaptive Biotechnologies stock at $40.30, your return over the last 4 years …Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to …Adaptive Biotechnologies is expected to report sales of $18.8 million, an decrease of 15.09% over the same period last year. With regard to the current fiscal year, analysts forecast a loss per ...

Adaptive Biotechnologies stock was originally listed at a price of $40.30 in Jun 27, 2019. If you had invested in Adaptive Biotechnologies stock at $40.30, your return over the last 4 years would have been -89.7%, for an annualized return of -43.35% (not including any dividends or dividend reinvestments).Adaptive Biotechnologies is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Adaptive Biotechnologies's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Adaptive Biotechnologies or its management.

Adaptive is powering immune medicine in the most unique way—and we’re looking for individuals who want to build a story, not just a resume. If you want to go beyond the impossible—Adaptive is where you’ll discover your story. You’ll tackle big, interesting, highly impactful problems that lead to a future you can help write.Delmaine Donson. Adaptive Biotechnologies (NASDAQ:ADPT) stock fell ~10% on Tuesday after the company said it is terminating the services of its Chief Operating Officer Mark Adams by May.The ...Get the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing. See the performance outlook, earnings date, dividend yield, research reports and more for ADPT on NasdaqGS. SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to …Shares of Adaptive Biotechnologies ... The clinical-stage biotech company's stock closed last week at $7.31, then rose to as high as $9.08 on Wednesday. The stock is up a little more than 10% so ...Adaptive common stock is expected to begin trading on The Nasdaq Global Select Market on June 27, 2019, under the ticker symbol “ADPT.” The offering is expected to close on July 1, 2019, subject to the satisfaction of customary closing conditions. ... About Adaptive Biotechnologies

Nov 30, 2023 · The average twelve-month price prediction for Adaptive Biotechnologies is $9.50 with a high price target of $15.00 and a low price target of $6.00. Learn more on ADPT's analyst rating history. Do Wall Street analysts like Adaptive Biotechnologies more than its competitors? Analysts like Adaptive Biotechnologies less than other Medical companies.

Adaptive Biotechnologies has an immune medicine platform used for sequencing T cells and developing a wide array of diagnostic and clinical products. ... If a stock tanks 80%, ...

It should be noted that over the last three months, corporate insiders have sold a total of 248,613 shares of Adaptive Biotechnologies stock, with a cumulative value of $2,006,083. As a result, corporate insiders now hold 5.20% of the company’s stock.THOUSAND OAKS, Calif., and SEATTLE, April 2, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Adaptive Biotechnologies (NASDAQ:ADPT) today announced a collaboration aimed at helping address the COVID-19 pandemic. The companies will combine expertise to discover and develop fully human neutralizing …Jun 2, 2023 · As of June 02, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $7.46. Adaptive Biotechnologies Corp is up 5.82% from its previous closing price of $7.05. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $6.76 and $7.14. Currently, there are 143.51 million shares of Adaptive ... Adaptive Biotechnologies presently has a consensus target price of $9.50, suggesting a potential upside of 102.13%. Immatics has a consensus target price of $17.67, suggesting a potential upside of 96.08%. Given Adaptive Biotechnologies' higher possible upside, analysts plainly believe Adaptive Biotechnologies is more favorable than Immatics.Adaptive Biotechnologies (ADPT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the ...Earlier this year, an enthusiastic market more than doubled the price of Adaptive Biotechnologies stock. Now that shares are trading around 22% below their recent peak, investors are wondering if ...Adaptive Biotechnologies is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Adaptive Biotechnologies's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Adaptive Biotechnologies or its management.Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.Find the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Adaptive Biotechnologies ...SEATTLE, June 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in several oral and poster presentations investigating the clinical ...Adaptive Biotechnologies Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Adaptive Biotechnologies Corp’s trailing 12-month revenue is $189.6 million with a -100.7% profit margin. Year-over-year quarterly sales growth most recently was 11.9%.Adaptive Biotechnologies Corp (NASDAQ:ADPT) 4.64 Delayed Data As of Nov 29 +0.27 / +6.18% Today’s Change 2.61 Today ||| 52-Week Range 10.79 -39.27% Year-to-Date Quote Profile News Charts...

According to the Biotechnology Industry Organization, there are more than 250 biotechnology products available, including medicines, vaccines, fertilizers, pest-resistant crops, bio-fuels and bio-defense products.If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...What percentage of Adaptive Biotechnologies stock is owned by insiders? 5.20% of Adaptive Biotechnologies stock is owned by insiders. Learn more on ADPT's insider holdings.Instagram:https://instagram. no tax return mortgageindustrial property investmenttop financial advisors in new yorkretirement planning today course review Nov 9, 2023 · SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ... Andris Zoltners ADPT stock SEC Form 4 insiders trading. Andris has made over 2 trades of the Adaptive Biotechnologies stock since 2020, according to the Form 4 filled with the SEC. Most recently Andris sold 345,000 units of ADPT stock worth $9,142,500 on 28 January 2020.. The largest trade Andris's ever made was selling 345,000 units of … best mortgage providers for first time buyersvktx nasdaq SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ... best art insurance Dec 4, 2023 · The consensus among analysts is that Adaptive Biotechnologies Corp (ADPT) is an Overweight stock at the moment, with a recommendation rating of 1.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 8 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. This page is intended for a US-based audience. clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with …